1. Chen, Wenyu, Zhang, Ye, Fang, Zhixian, Qi, Weibo, Xu, Yufen. 2022. TRIM66 hastens the malignant progression of non-small cell lung cancer via modulating MMP9-mediated TGF-β/SMAD pathway. In Cytokine, 153, 155831. doi:10.1016/j.cyto.2022.155831. https://pubmed.ncbi.nlm.nih.gov/35301175/
2. Mielnicka, Monika, Tabaro, Francesco, Sureka, Rahul, Remans, Kim, Boulard, Matthieu. 2024. Trim66's paternal deficiency causes intrauterine overgrowth. In Life science alliance, 7, . doi:10.26508/lsa.202302512. https://pubmed.ncbi.nlm.nih.gov/38719749/
3. Cao, Hongwen, Gao, Renjie, Chen, Lei, Feng, Yigeng. 2020. TRIM66 promotes malignant progression of prostate carcinoma through the JAK/STAT pathway. In FEBS open bio, 10, 515-524. doi:10.1002/2211-5463.12798. https://pubmed.ncbi.nlm.nih.gov/31981447/
4. Xu, Yufen, Yang, Qi, Fang, Zhixian, Zhang, Ming, Chen, Wenyu. 2022. TRIM66 Promotes Malignant Progression of Non-Small-Cell Lung Cancer Cells via Targeting MMP9. In Computational and mathematical methods in medicine, 2022, 6058720. doi:10.1155/2022/6058720. https://pubmed.ncbi.nlm.nih.gov/35912155/
5. Zhang, H-G, Pan, Y-W, Feng, J, Liang, B, Zhang, W-W. . TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway. In European review for medical and pharmacological sciences, 23, 2003-2012. doi:10.26355/eurrev_201903_17239. https://pubmed.ncbi.nlm.nih.gov/30915743/
6. Chen, Yu, Guo, Yongfei, Yang, Haisong, Yin, Na, Chen, Deyu. . TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome. In Oncotarget, 6, 23708-19. doi:. https://pubmed.ncbi.nlm.nih.gov/26247633/
7. Fan, Wanhu, Du, Fenjing, Liu, Xiaojing. 2019. TRIM66 confers tumorigenicity of hepatocellular carcinoma cells by regulating GSK-3β-dependent Wnt/β-catenin signaling. In European journal of pharmacology, 850, 109-117. doi:10.1016/j.ejphar.2019.01.054. https://pubmed.ncbi.nlm.nih.gov/30710548/
智鼠故事 
